Clinical Trials Logo

Clinical Trial Summary

In this protocol, the investigators hypothesize that modifying the process of producing CAR+ T-cells can help to improve responses and reduce toxicities. Building on previous in vitro studies that have shown successful production of CAR+ T-cells using a new production approach, the investigators are now studying the ability to produce these CAR+ T-cells and determine how well they work in the clinical setting.


Clinical Trial Description

Autologous peripheral blood mononuclear cell (PBMC) will be obtained by leukapheresis over one day and the cells will be transduced with an in house designed CAR retroviral vector. Participants will receive daily intravenous (IV) infusion of lymphodepleting regimen of fludarabine and cyclophosphamide for total of 3 days (Days -5, -4, -3). The dose of cyclophosphamide will be given at 500mg/m2. The dose of fludarabine will be given at 30mg/m2. Participants will receive the CAR transduced T cells IV infusion in the BMT Inpatient Unit and remain admitted for close monitoring for at least the first 7 days following the cell infusion (D0 to Day +7), possibly longer if any side effects are encountered. The CAR transduced T cells will be escalated from 1 x 106 transduced T cells/kg (± 20%) to 2 x 106 transduced T cells/kg (± 20%) in a Phase I design, based on toxicity. Once discharged from the inpatient unit, for the next 7 days (Day +8 to Day +14) the patients will be evaluated in the High Dose Unit (labs and physical exam) to screen for toxicities. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04214886
Study type Interventional
Source Loyola University
Contact
Status Active, not recruiting
Phase Phase 1
Start date December 31, 2019
Completion date December 31, 2034

See also
  Status Clinical Trial Phase
Enrolling by invitation NCT05645744 - Long-term Follow-up Study in Patients Previously Treated With a Mustang Bio CAR-T Cell Investigational Product.
Active, not recruiting NCT03664635 - MB-CART20.1 Lymphoma Phase 1/Phase 2
Recruiting NCT03853616 - MB-CART19.1 r/r CD19+ B-cell Malignancies (BCM) Phase 1/Phase 2
Recruiting NCT06445803 - CD19/CD22 CAR-T Cells in Adults With R/R ALL or NHL Phase 1
Recruiting NCT05360238 - Study to Assess Safety, Tolerability and Efficacy of MB-106 in Patients With Relapsed or Refractory B-Cell NHL or CLL Phase 1/Phase 2
Not yet recruiting NCT04303247 - CD19 and CD22 Dual-targeted CAR-T Cells for Relapsed or Refractory B-NHL Early Phase 1
Recruiting NCT05318963 - Targeting CD19/CD20/CD22 Triple-targeted Cell in Patients With Relapsed/Refractory B-cell Lymphoma Phase 1
Active, not recruiting NCT04531046 - Axi-Cel as a 2nd Line Therapy in Patients With Relapsed/Refractory Aggressive B Lymphoma Ineligible to Autologous Stem Cell Transplantation Phase 2
Not yet recruiting NCT05705570 - A Phase I Clinical Trial Using Genetically Engineered Autologous T Cells to Express Chimeric Antigen Receptor (CAR) for Treatment of Patients With Refractory or Relapsed CD19-positive B Lymphoid Malignancies Phase 1
Active, not recruiting NCT04304040 - A Study of MIL62 Combined With Orelabrutinib for the Treatment of R/R CD20+B Cell Lymphoma Phase 1/Phase 2
Not yet recruiting NCT05909098 - Safety and Efficacy of Autologous NK Cell Adjuvant Therapy for Relapsed/Refractory Non-Hodgkin's B-cell Lymphoma Phase 1/Phase 2
Recruiting NCT04747093 - Induced-T Cell Like NK Cells for B Cell Malignancies Phase 1/Phase 2
Completed NCT05130489 - CAR T Cell Therapy Related Cardiovascular Outcomes
Recruiting NCT01786018 - Thiotepa, Busulfan and Fludarabin for pt With Refractory/Early Relapsed Aggressive B-cell Non Hodgkin Lymphomas Phase 2
Recruiting NCT06220097 - Mitoxantrone Hydrochloride Liposome Injection-containing Bridging Regimen and CD19-targeting CAR-T Therapies Phase 2
Completed NCT01535989 - Study of Inotuzumab Ozogamicin + Temsirolimus in Patients With Relapsed or Refractory CD22+ B-cell NHLymphoma Phase 1